FDA accepts Outlook Therapeutics’ resubmitted BLA for LYTENAVA™ in wet AMD, assigning a July 29, 2026 PDUFA date. The Class 1 review follows a CRL, dispute resolution, and OND efficacy backing.
Written By: Sana Khan, BPharm
Reviewed By: Pharmacally Editorial Team
The U.S. Food and Drug Administration (FDA) has accepted Outlook Therapeutics’ resubmitted Biologics License Application (BLA) for LYTENAVA™ (bevacizumab-vikg) for the treatment of neovascular age-related macular degeneration (wet AMD), months after the agency’s Office of New Drugs overturned an earlier efficacy-related Complete Response Letter. The application received a Class 1 review designation and a Prescription Drug User Fee Act (PDUFA) target action date of July 29, 2026, moving the therapy into the final stage of regulatory review.
If approved, LYTENAVA would become the first FDA-approved ophthalmic formulation of bevacizumab in the United States, providing retina specialists with a standardized anti-VEGF therapy supported by FDA-reviewed labeling, controlled manufacturing, and formal pharmacovigilance requirements.
Scientific and Clinical Context
Wet AMD is a leading cause of vision loss among older adults and is driven by abnormal vascular endothelial growth factor (VEGF)-mediated blood vessel growth and leakage beneath the retina. LYTENAVA is an anti-VEGF monoclonal antibody developed specifically for intravitreal administration to reduce retinal neovascularization and vascular leakage associated with the disease.
Regulatory History
LYTENAVA’s U.S. regulatory pathway has included several notable developments. In December 2025, the FDA issued a Complete Response Letter (CRL), citing insufficient evidence of efficacy. Outlook Therapeutics subsequently held a Type A meeting with the agency and initiated a Formal Dispute Resolution (FDR) process.
In May 2026, the FDA’s Office of New Drugs (OND) concluded that efficacy data from the pivotal NORSE TWO trial, supported by findings from NORSE EIGHT and mechanistic evidence, provided substantial evidence of effectiveness. The OND decision overturned the earlier efficacy determination and directed the Division of Ophthalmology to work with the company on labeling discussions.
The FDA has now accepted the resubmitted BLA as a Class 1 review, advancing the therapy toward a final regulatory decision.
Regulatory and Development Background
The Class 1 designation typically carries a two-month review timeline and is generally reserved for narrower amendments to a previously submitted application. The acceptance indicates that the agency has determined the resubmission is sufficiently complete to proceed with final review.
LYTENAVA has already secured regulatory approvals for wet AMD in the European Union and the United Kingdom, where it is marketed as bevacizumab gamma.
Chief Executive Officer Bob Jahr said the FDA’s acceptance marks an important step toward potential approval and reflects the company’s efforts to establish a regulated ophthalmic bevacizumab option for retina specialists and patients in the United States.
Commercial and Regulatory Outlook
Outlook Therapeutics has initiated pre-launch activities in anticipation of a potential approval, signaling preparations for commercialization should the FDA issue a positive decision. The company expects to continue working with the FDA on labeling discussions ahead of the July 29, 2026 PDUFA date.
A favorable outcome could introduce a standardized, FDA-approved ophthalmic bevacizumab therapy to the U.S. market and provide physicians with an alternative to repackaged bevacizumab products commonly used in clinical practice.
What This Means for Patients
The FDA’s acceptance of the resubmitted application does not immediately change treatment options for people living with wet AMD. Patients will continue to receive currently available anti-VEGF therapies while the agency completes its review.
If approved, LYTENAVA could become the first FDA-approved ophthalmic formulation of bevacizumab in the United States. Today, many retina specialists use repackaged bevacizumab off-label for wet AMD because it is a lower-cost alternative to other anti-VEGF medicines. An approved ophthalmic version would provide a product manufactured specifically for use in the eye and supported by FDA-reviewed labeling, standardized quality controls, and formal safety monitoring.
For patients, this could expand treatment choice by providing a regulated bevacizumab option manufactured specifically for ophthalmic use while maintaining a familiar anti-VEGF mechanism already widely used in retinal care. The next key milestone is the FDA’s decision, expected by July 29, 2026.
Reference
About the Writer
Sana Jamil Khan (LinkedIn) is a B. Pharm graduate with a strong interest in medical writing and scientific communication. Her work focuses on interpreting clinical research, exploring developments in pharmaceutical science, and presenting complex medical information in a clear and accessible manner. She is particularly interested in topics related to human clinical studies, drug safety observations, and emerging therapeutic research.